Bupropion IR Duration of Action
Bupropion immediate-release (IR) has a duration of action of approximately 4-6 hours, requiring three-times-daily dosing to maintain therapeutic blood levels.
Pharmacokinetic Profile
Bupropion IR is absorbed rapidly after oral administration, with peak plasma concentrations reached within approximately 1.5-2 hours 12. The drug undergoes biphasic elimination:
- Alpha phase half-life: ~1.5 hours
- Beta phase half-life: ~14 hours (for the parent compound) 1
However, the clinically relevant duration of action is much shorter than the elimination half-life would suggest, necessitating multiple daily doses.
Dosing Requirements
The FDA-approved dosing for bupropion IR reflects its short duration of action 3:
- Standard dosing: Three times daily (TID)
- Typical dose range: 75-100 mg per dose
- Maximum daily dose: 450 mg (divided into three doses)
This TID dosing schedule is required because therapeutic blood concentrations decline relatively quickly after each dose, despite the longer elimination half-life of the parent compound.
Active Metabolites Extend Overall Effect
While the parent drug has a relatively short duration, bupropion's active metabolites have longer half-lives 2:
- Hydroxybupropion: ~20 hours (primary active metabolite)
- Threohydrobupropion: ~37 hours
- Erythrohydrobupropion: ~33 hours
These metabolites contribute to the overall antidepressant effect but accumulate with repeated dosing. The immediate-release formulation still requires TID dosing to maintain stable therapeutic levels of both parent drug and metabolites.
Clinical Implications
For practical purposes, each dose of bupropion IR provides approximately 4-6 hours of peak therapeutic effect, which is why:
- Doses should be spaced at least 4 hours apart to minimize seizure risk 3
- The medication must be taken three times daily for consistent symptom control
- Missing a single dose can result in subtherapeutic drug levels
Comparison to Other Formulations
The short duration of bupropion IR led to development of longer-acting formulations 24:
- Sustained-release (SR): Dosed twice daily (BID), with Tmax ~3 hours
- Extended-release (XL): Dosed once daily (QD), with Tmax ~5 hours
These formulations provide more stable plasma concentrations and improved convenience, though they are bioequivalent to IR at steady state 2.
Key Caveats
- The 14-hour elimination half-life refers to the terminal phase and does not reflect the duration of therapeutic action
- Extensive first-pass metabolism means oral bioavailability is significantly reduced 1
- Individual variation exists based on CYP2B6 activity, though pharmacogenomic studies have not shown clinically significant differences in major PK parameters 5